Protagenic Therapeutics, Inc.\new
PTIX evidence brief
What we can confirm
- BioSniper Score:
- 9.6 / 10
- Market Cap:
- $1.6M
What it means
What to watch
Prepared research question
What matters most for PTIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTIX
Protagenic Therapeutics, Inc. (PTIX) is a developmental-stage biopharmaceutical company focused on a single neuropeptide product candidate, PT00114, targeting the TCAP pathway for generalized anxiety disorder, with no approved products and limited cash runway.
Key risk: Cash runway exhaustion
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Protagenic Therapeutics, Inc. (PTIX) is a developmental-stage biopharmaceutical company focused on a single neuropeptide product candidate, PT00114, targeting the TCAP pathway for generalized anxiety disorder, with no approved products and limited cash runway.
- Lead candidate PT00114 targets the teneurin C-terminal associated peptide (TCAP) pathway for generalized anxiety disorder (GAD) [sec · filed 2026-08-20].
- As of June 30, 2026, the company had cash of $565,985 and a working capital deficit of $362,743, with cash resources expected to fund operations only until approximately the end of Q3 2026 [sec_mda · as of 2026-08-19].
- Net loss for the period ended June 30, 2026 was -$1.0M, with shareholders' equity of $1.7M [latest reported financials].
- The company has received FDA written responses to its Type B pre-IND meeting request for PT00114 and intends to submit the IND before end of 2026, targeting first patient dosing in H1 2027 [sec · filed 2026-08-20].
- The company is transitioning to a virtual operating model to minimize cash burn while prioritizing its clinical-stage program [sec_mda · as of 2026-08-14].
What works
- The company has obtained FDA pre-IND feedback for PT00114, a key regulatory milestone that de-risks the path to clinical trials [sec · filed 2026-08-20].
- Management has implemented a restructuring plan focused on a single clinical program and a virtual operating model to conserve cash [sec_mda · as of 2026-08-14].
- The company has a clearly defined near-term catalyst: IND submission by end of 2026 and first patient dosing in H1 2027 [sec · filed 2026-08-20].
What to weigh
- Cash runway is extremely limited — as of June 30, 2026, cash of $565,985 is expected to fund operations only until approximately end of Q3 2026, with no committed sources of additional capital [sec_mda · as of 2026-08-19].
- The company has no approved products and no revenue, and anticipates continued losses for the foreseeable future [sec_mda · as of 2026-08-19].
- FDA pre-IND advice is non-binding; the FDA may raise additional questions, request more data, impose a clinical hold, or otherwise delay the program [sec · filed 2026-08-20].
- The company's financial history is complicated by a reverse merger with Phytanix Bio, limiting comparability of financial data across periods [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
Cash position and runway
“As of June 30, 2026, we had cash of $565,985 and working capital deficit of $362,743. We anticipate that losses will continue for the foreseeable future. Based on our current operating plans, we believe that our cash resources will be sufficient to fund its operations until approximately the end of the third quarter of 2026.”
SEC MD&A · August 19, 2026
FDA pre-IND feedback and planned timeline
“the Company's Type B pre-IND meeting request for PT00114, the Company's lead investigational neuropeptide product candidate targeting the teneurin C-terminal associated peptide ("TCAP") pathway, for the treatment of GAD. Based on the FDA's feedback, the Company currently intends to submit the IND before the end of 2026 and is targeting first patient dosing in the first half of 2027”
SEC filings · August 20, 2026
Restructuring to virtual model
“Virtual operating model. The Company is transitioning to a virtual operating model to minimize cash burn while prioritizing its clinical-stage program.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Cash runway exhaustion — Cash of $565,985 as of June 30, 2026 expected to last only until end of Q3 2026; no committed capital sources [sec_mda · as of 2026-08-19].
- FDA non-binding advice risk — FDA pre-IND advice is non-binding; agency may raise new questions, request more data, or impose clinical hold [sec · filed 2026-08-20].
- No approved products or revenue — Company has no approved products and no sales revenue; relies entirely on external funding [sec_mda · as of 2026-08-19].
- Single-asset dependency — Entire pipeline is one preclinical candidate (PT00114); any setback halts the company's program [sec · filed 2026-08-20].
What to watch
- IND submission for PT00114 before end of 2026 [sec · filed 2026-08-20]
- First patient dosing target in H1 2027, subject to FDA clearance [sec · filed 2026-08-20]
- Ability to raise additional capital given cash runway ends Q3 2026 [sec_mda · as of 2026-08-19]
- Completion of ongoing Phase 2 clinical trial of PT00114 (peptide analogue) expected in 9-12 months [sec_mda · as of 2026-08-14]
Sources: SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Protagenic Therapeutics, Inc.\new through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Protagenic Therapeutics, Inc.\new facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.62 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
5 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$28K
| Holder | Shares | Value |
|---|---|---|
| drw securities, llc | 41,783 | $28K |
| corecap advisors, llc | 100 | $68 |
| fny investment advisers, llc | 25,000 | $16 |
| united financial planning group llc | 17 | $12 |
Governance
Frequently asked questions
What is the AI investment thesis for Protagenic Therapeutics, Inc.\new?
Protagenic Therapeutics, Inc. (PTIX) is a developmental-stage biopharmaceutical company focused on a single neuropeptide product candidate, PT00114, targeting the TCAP pathway for generalized anxiety disorder, with no approved products and limited cash runway.
Who is the CEO of Protagenic Therapeutics, Inc.\new?
Timothy R. Wright is the chief executive officer of Protagenic Therapeutics, Inc.\new (PTIX).
Where is Protagenic Therapeutics, Inc.\new headquartered?
Protagenic Therapeutics, Inc.\new (PTIX) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.